# Study to Evaluate Safety and Tolerability of ACT-709478 in Healthy Subjects

> **NCT03165097** · PHASE1 · COMPLETED · sponsor: **Idorsia Pharmaceuticals Ltd.** · enrollment: 46 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** ACT-709478
- **DRUG:** Placebo
- **DRUG:** Midazolam
- **DRUG:** ACT-709478 combined with midazolam

## Key facts

- **NCT ID:** NCT03165097
- **Lead sponsor:** Idorsia Pharmaceuticals Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-07
- **Primary completion:** 2018-11-15
- **Final completion:** 2018-12-28
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2019-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03165097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03165097, "Study to Evaluate Safety and Tolerability of ACT-709478 in Healthy Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03165097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*